(S)-2-hydroxy-2-((4R,4'R,5R)-2,2,2',2'-tetramethyl-[4,4'-bi(1,3-dioxolan)]-5-yl)ethyl 5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate | 1569406-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环七噻吩
• 英文名称: (S)-2-hydroxy-2-((4R,4'R,5R)-2,2,2',2'-tetramethyl-[4,4'-bi(1,3-dioxolan)]-5-yl)ethyl 5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate
• 英文别名: [(2S)-2-[(4R,5R)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyethyl] 5-[3-[(1R,2R,3R,5R)-5-chloro-2-[2-(3,5-dichlorophenyl)ethyl]-3-hydroxycyclopentyl]propyl]thiophene-2-carboxylate
• CAS: 1569406-77-4
• 化学式: C₃₃H₄₃Cl₃O₈S
• 分子量: 706.125
• InChiKey: KBDMLGLXXNSAPJ-QHBCGUIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES
  申请人：ALLERGAN, INC.

  公开号：US20140057975A1

  公开（公告）日：2014-02-27

  Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.

  本发明提供了治疗青光眼的组合物和方法。具体提供了亲水性酯前药及其用于减少中央角膜增厚的使用方法。
• US9024042B2
  申请人：——

  公开号：US9024042B2

  公开（公告）日：2015-05-05
• US9090595B2
  申请人：——

  公开号：US9090595B2

  公开（公告）日：2015-07-28
• US9427401B2
  申请人：——

  公开号：US9427401B2

  公开（公告）日：2016-08-30
• [EN] REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES<br/>[FR] ÉPAISSISSEMENT RÉDUIT DE LA CORNÉE CENTRALE À L'AIDE DE PROMÉDICAMENTS ESTERS HYDROPHILES DE BÊTA-CHLOROCYCLOPENTANES
  申请人：ALLERGAN INC

  公开号：WO2014035827A1

  公开（公告）日：2014-03-06

  Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs of formula (I) and formula (III) and said compounds for use to reduce central corneal thickening is provided, wherein L1 -L3, R1 and R2 are as defined in claim 1 and n and R2D as defined in claim 37. Formula (I), Formula (III).